Small molecule · Antagonist of thromboxane-prostanoid receptor (TBXA2R) · developed by Cumberland Pharmaceuticals
Ifetroban is an orally bioavailable thromboxane and prostaglandin H2 receptor antagonist that prevents platelet activation, aggregation, and thrombosis while promoting vasodilation. It is studied in scleroderma, idiopathic pulmonary fibrosis, aspirin-exacerbated asthma, and dilated cardiomyopathy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05571059 | Phase 2 | Idiopathic Pulmonary Fibrosis | Recruiting | CPIX |
| NCT03340675 | Phase 2 | Duchenne Muscular Dystrophy Cardiomyopathy | Completed | CPIX |
| NCT03028350 | Phase 2 | Asthma, Aspirin-Induced | Completed | CPIX |
| NCT02682511 | Phase 2 | Scleroderma, Diffuse | Active not recruiting | CPIX |
| NCT02216357 | Phase 2 | Aspirin Exacerbated Respiratory Disease (AERD) | Completed | CPIX |
| NCT01436500 | Phase 2 | Hepatorenal Syndrome | Completed | CPIX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Autoimmune DiseasesConnective Tissue DiseasesIdiopathic Pulmonary FibrosisPathologic ProcessesScleroderma, DiffuseScleroderma, LimitedScleroderma, SystemicSclerosis, Progressive SystemicSkin DiseasesAspirin Exacerbated Respiratory Disease (AERD)Asthma, Aspirin-InducedCardiomyopathy, DilatedDuchenne Muscular Dystrophy CardiomyopathyHepatorenal Syndrome
Updated Oct 3, 2026. Something wrong or missing? Report it on the CPIX page.
See CPIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CPIX catalysts and pipeline →